Barbara Bodem

CFO, Hill-Rom Holdings, Inc.

Barbara W. Bodem was appointed senior vice president and chief financial officer of Hill-Rom Holdings, Inc. in December 2018. Ms. Bodem joined Hill-Rom from Mallinckrodt Pharmaceuticals, where she served as senior vice president, Finance. Earlier in her career Ms. Bodem worked at Hospira as vice president, Global Commercial Finance, as well as at Eli Lilly and Company, where she held a variety of Finance roles in the U.S. and the U.K., including serving as CFO for Lilly Oncology. Ms. Bodem recently served as a member of the board of directors of Invacare Corporation. She earned her BS in finance and MBA from Indiana University.

Ms. Bodem serves as chair of the audit committee.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb